This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The quarterly cost of dupilumab would have to drop from $7311 to $2038.50 for the biologic to be cost effective relative to tCS and to $302.55 to be cost effective relative to PPI therapy, ...

Not surprisingly, both Katz and Dellon pointed to dupilumab's cost and the related challenge of convincing insurance companies to cover the drug as major challenges to more widespread use.

Learn about side effects, cost, and more of Dupixent (dupilumab). It’s a prescription drug that treats atopic dermatitis (a type of eczema) and other conditions.

Dupilumab users had at least 0.5 fewer exacerbations per person per 1.5 years compared with other biologics. Impacts were greater among patients with histories of two or more exacerbations.

additional costs applied to non-responders to account for the cost of treatment failure (see section 3.12). When taking into account the confidential discount for dupilumab, the company's base-case ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab, a fully human monoclonal antibody, ... Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol 2018;16(4) ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...

Dupilumab : This newer medication, for eczema that doesn't respond to other treatments, has copays of $60 to $125, according to one online service. Always compare prices for your medications among ...

Out-of-pocket cost: This is the amount a person must pay for care when Medicare does not pay the total amount or offer coverage. Costs can include deductibles, coinsurance, copayments, and premiums.